Loading clinical trials...
Loading clinical trials...
A Multicenter, Dose-Optimized, Open-Label, Safety/Tolerability and Pharmacokinetic Study With Azstarys® in Children 4 and 5 Years of Age With Attention-Deficit/Hyperactivity Disorder
Conditions
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Locations
20
United States
Preferred Research Partners (PRP)
Little Rock, Arkansas, United States
Advanced Research Center (ARC)
Anaheim, California, United States
IMMUNOe International Research Center
Centennial, Colorado, United States
Clinical Neuroscience Solutions - Orlando
Jacksonville, Florida, United States
Accel Research Sites - Lakeland
Lakeland, Florida, United States
Accel Research Sites - Maitland
Maitland, Florida, United States
Start Date
June 2, 2023
Primary Completion Date
August 29, 2025
Completion Date
August 29, 2025
Last Updated
September 10, 2025
NCT06133231
NCT03136263
NCT04189562
NCT02333149
NCT01682915
NCT00907218
Lead Sponsor
Corium, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions